Here is an undiscovered Stock with Monster Upside
Post# of 124
Posted On: 05/26/2016 1:22:46 PM
Here is an undiscovered Stock with Monster Upside Potential which just trading at cash level . Aytu Biosciences bought US Rights to Natesto the only approved testosterone nasal gel which targets a $2+ BILLION Market which they start selling in July . The Company has another 3 Products on the Market and another One Big drug ready for Phase 3 . AYTU has a ridiculous Market Cap of just $14 Million which is below the Cash balance of $15 Million means you get the Company and Products for free . The Stock has minumum ipside Potential of 700% .
In April, AYTU signed an exclusive license agreement for the U.S. commercial rights to Natesto® (testosterone) Nasal Gel. Natesto is the first and only nasal formulation of testosterone approved by the U.S. Food and Drug Administration (FDA) as a replacement therapy for men diagnosed with hypogonadism (low testosterone, or “Low T”). Aytu anticipates further expanding its current urology-centric sales force and initiating its promotion of Natesto into the $2 billion U.S. testosterone replacement market in July 2016.
Aytu Bioscience (AYTU)
Market Cap: $14 Million
Cash: $15 Million
Price: $0.32
Shares Out: 44.86 Million
Marketed Products:
PRIMSOL : Only FDA-approved trimethoprim oral solution; indicated for urinary tract infections
ProstaScint : Only FDA-approved imaging agent for prostate cancerdetection and staging
MIOXSYS : CE Marked in vitro diagnostic device for male infertility , Single FDA study pending
Acquired Exclusive U.S. Rights to Natesto April 2016 (US Market Launch July)
•Only FDA-approved, nasally-administered testosterone; indicated for hypogonadism
•Approved for use WITHOUT black box warning related to partner transference
ZERTANE
hase 3-ready, effective first-in-class oral treatment for premature ejaculation
Presentation May 2016
http://aytubio.com/downloads/Aytu-Corporate-Overview.pdf
Aytu BioScience Initiates Commercial Expansion to Support July 2016 Launch of Natesto®
http://finance.yahoo.com/news/aytu-bioscience...00542.html
Insider Buying:
May 6, 2016 DISBROW JOSHUA R. Officer direct Buy 0.40 250,000
May 6, 2016 DISBROW JARRETT Officer direct Buy 0.40 250,000
May 6, 2016 DOCKERY CARL Director indirect Buy 0.40 5,000,000
Jan 20, 2016 DISBROW JOSHUA R. Officer direct Buy 0.65 153,846
Jan 20, 2016 DISBROW JARRETT Officer direct Buy 0.65 153,846
In April, AYTU signed an exclusive license agreement for the U.S. commercial rights to Natesto® (testosterone) Nasal Gel. Natesto is the first and only nasal formulation of testosterone approved by the U.S. Food and Drug Administration (FDA) as a replacement therapy for men diagnosed with hypogonadism (low testosterone, or “Low T”). Aytu anticipates further expanding its current urology-centric sales force and initiating its promotion of Natesto into the $2 billion U.S. testosterone replacement market in July 2016.
Aytu Bioscience (AYTU)
Market Cap: $14 Million
Cash: $15 Million
Price: $0.32
Shares Out: 44.86 Million
Marketed Products:
PRIMSOL : Only FDA-approved trimethoprim oral solution; indicated for urinary tract infections
ProstaScint : Only FDA-approved imaging agent for prostate cancerdetection and staging
MIOXSYS : CE Marked in vitro diagnostic device for male infertility , Single FDA study pending
Acquired Exclusive U.S. Rights to Natesto April 2016 (US Market Launch July)
•Only FDA-approved, nasally-administered testosterone; indicated for hypogonadism
•Approved for use WITHOUT black box warning related to partner transference
ZERTANE
hase 3-ready, effective first-in-class oral treatment for premature ejaculation Presentation May 2016
http://aytubio.com/downloads/Aytu-Corporate-Overview.pdf
Aytu BioScience Initiates Commercial Expansion to Support July 2016 Launch of Natesto®
http://finance.yahoo.com/news/aytu-bioscience...00542.html
Insider Buying:
May 6, 2016 DISBROW JOSHUA R. Officer direct Buy 0.40 250,000
May 6, 2016 DISBROW JARRETT Officer direct Buy 0.40 250,000
May 6, 2016 DOCKERY CARL Director indirect Buy 0.40 5,000,000
Jan 20, 2016 DISBROW JOSHUA R. Officer direct Buy 0.65 153,846
Jan 20, 2016 DISBROW JARRETT Officer direct Buy 0.65 153,846
(0)
(0)